MAPK
Las MAPK son una familia de quinasas de proteínas involucradas en una variedad de procesos celulares, incluyendo crecimiento, proliferación, diferenciación y respuestas al estrés. La vía de señalización MAPK consta de varios niveles, incluidos ERK, JNK y p38 MAPK, cada uno con roles distintos en la función celular. La desregulación de la señalización MAPK está vinculada al cáncer, las enfermedades inflamatorias y los trastornos metabólicos. En CymitQuimica, ofrecemos una amplia gama de inhibidores y activadores de MAPK para apoyar su investigación en biología celular, transducción de señales y mecanismos de enfermedades.
Se han encontrado 881 productos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
HPK1-IN-30
CAS:<p>HPK1-IN-30 is a potent inhibitor of HPK1. HPK1-IN-30 has potential for cancer disease research.</p>Fórmula:C25H23FN6Forma y color:SolidPeso molecular:426.49ATX inhibitor 26
CAS:<p>ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. It effectively inhibits cell migration and collagen gel contraction. Additionally, ATX inhibitor 26 demonstrates significant antifibrotic activity, reducing collagen deposition in a Bleomycin (BLM)-induced pulmonary fibrosis model.</p>Fórmula:C18H19Cl2N7O3Forma y color:SolidPeso molecular:452.30K-Ras-IN-4
CAS:K-Ras-IN-4 (compound CP163) is an inhibitor of K-Ras.Fórmula:C31H28F4N6O3SForma y color:SolidPeso molecular:640.65VVD-699
CAS:<p>VVD-699 is a covalent inhibitor of RAS-PI3K. It forms a covalent bond with cysteine at position 242 within the RAS-binding domain of PI3Kp110α, thereby obstructing the ability of RAS to activate PI3K. VVD-699 is capable of inhibiting the growth of tumors with RAS mutations and HER2 overexpression. It is applicable in research related to RAS mutation-associated cancers, such as those involving H358 lung cancer cells, A549 cells, and FaDu cells.</p>Fórmula:C25H30ClFN2O6S2Forma y color:SolidPeso molecular:573.097SHR2415
<p>SHR2415: Potent, selective ERK1/2 inhibitor, oral; ERK1 IC50: 2.8 nM, ERK2 IC50: 5.9 nM; effective in Colo205 (IC50: 44.6 nM), for cancer research.</p>Fórmula:C23H22ClN7O2Forma y color:SolidPeso molecular:463.92HPK1-IN-55
CAS:<p>HPK1-IN-55 (compound 19) is a selective and orally active inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 of less than 0.51 nM. It exhibits exceptional kinase selectivity, being over 637 times more selective for HPK1 compared to GCK kinase and over 1022 times compared to LCK. HPK1-IN-55 possesses anti-cancer properties.</p>Fórmula:C30H34N8O3Forma y color:SolidPeso molecular:554.643KRAS G12C inhibitor 50
CAS:<p>KRAS G12C inhibitor 50 is a KRAS G12C inhibitor (IC50: 46.7 nM).</p>Fórmula:C31H34N8O2Forma y color:SolidPeso molecular:550.65MCB-22-174
CAS:MCB-22-174 is a potent agonist of Piezo1 with an EC50 value of 6.28 µM. It activates Ca2+-related extracellular signal-regulated kinase and calcium-calmodulin (CaM)-dependent protein kinase II (CaMKII) pathways, and it promotes mesenchymal stem cell osteogenic differentiation, indicating its potential application in the study of disuse osteoporosis (OP).Fórmula:C16H14DCl2N5OS2Peso molecular:429.37KRAS G12D inhibitor 3
CAS:<p>KRAS G12D Inhibitor 3, a compound targeting the KRAS G12D mutation, demonstrates potent antitumor efficacy with an inhibitory concentration (IC50) of less than</p>Fórmula:C34H31ClF3N5O2Forma y color:SolidPeso molecular:634.09Sosimerasib
CAS:<p>Sosimerasib is an inhibitor of the kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antitumor activity.</p>Fórmula:C36H39ClFN7O4Forma y color:SolidPeso molecular:688.191MRTX849 ethoxypropanoic acid
CAS:<p>MRTX849 is a KRAS G12C ligand and PROTAC linker for creating potent LC-2, degrading KRAS G12C with DC50 of 0.25-0.76 μM.</p>Fórmula:C37H43ClFN7O5Forma y color:SolidPeso molecular:720.24KRAS G12D inhibitor 12
<p>KRAS G12D inhibitor 12 targets Ras protein for cancer research. (Patent WO2021108683A1, Compound 134)</p>Fórmula:C23H21ClFN5O3Forma y color:SolidPeso molecular:469.9SML-10-70-1
CAS:<p>SML-10-70-1 is a Novel Active Site Inhibitor of Oncogenic K-Ras G12C.</p>Fórmula:C25H42ClN7O13P2Forma y color:SolidPeso molecular:746.04Dorrigocin A
CAS:<p>Dorrigocin A, an analog of Migrastatin, inhibits the carboxymethyltransferase involved in Ras processing, reversing the morphology of Ras-transformed NIH/3T3 cells. Dorrigocin A holds potential for research as an anticancer and anti-arthritis agent.</p>Fórmula:C27H41NO8Forma y color:SolidPeso molecular:507.616ERK-IN-2
CAS:<p>ERK-IN-2, an ERK2 inhibitor, exhibits an IC50 value of 1.8 nM. At doses greater than 10 μM, it may induce off-target toxicity and/or activity [1].</p>Fórmula:C16H18ClN5O2Pureza:98%Forma y color:SolidPeso molecular:347.80SOF-436
CAS:<p>SOF-436 is a KRAS inhibitor that can suppress SOS1-mediated KRAS nucleotide exchange (IC50 = 60 μM) and inhibit the interaction between KRAS and the effector protein RAF. SOF-436 is applicable to cancer research.</p>Fórmula:C15H13F2NO4S2Forma y color:SolidPeso molecular:373.395JAK3-IN-13
<p>JAK3-IN-13: Oral JAK3 inhibitor, selective & potent. Acts on NK1, JNK2, JNK3, Tyk2. Anti-tumor. IC50: JNK3, 8 nM; Tyk2, 365 nM; JNK2, 2039 nM; NK1, 4728 nM.</p>Fórmula:C25H33ClN6O5Forma y color:SolidPeso molecular:533.02HPK1-IN-14
CAS:<p>HPK1-IN-14 is a potent inhibitor of HPK1. HPK1-IN-14 has potential for the study of HPK1-related diseases.</p>Fórmula:C24H23FN6O2Forma y color:SolidPeso molecular:446.48SOS1-IN-10
<p>SOS1-IN-10 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 13 nM).</p>Fórmula:C22H19F5N4OForma y color:SolidPeso molecular:450.4KRAS G12D inhibitor 1
CAS:<p>KRAS G12D inhibitor 1 (example 243) is an inhibitor of KRAS G12D with an IC 50 of 0.8 nM for KRAS G12D-mediated ERK phosphorylation [1].</p>Fórmula:C33H32F2N6O2Forma y color:SolidPeso molecular:582.64
